CBD for Social Anxiety Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two doses of CBD in willing participants to see if it helps reduce stress and fear by interacting with the body's natural systems. Oral administration of cannabidiol (CBD) has shown to yield a variety of therapeutic benefits among humans, particularly regarding symptoms of anxiety.
Do I have to stop taking my current medications to join the trial?
Yes, you must stop taking certain medications, especially psychotropic drugs like antipsychotics, anticonvulsants, benzodiazepines, and opioids, as well as medications that affect specific liver enzymes, at least 4 weeks before starting the trial.
Is CBD safe for humans?
How does the drug CBD differ from other treatments for social anxiety disorder?
CBD is unique because it is a non-addictive component of the cannabis plant that reduces anxiety without causing sedation, unlike many traditional anxiety medications. It works quickly and has shown promise in reducing social anxiety symptoms in both single and repeated doses, making it a potentially effective alternative for those who do not respond well to existing treatments.12678
What evidence supports the effectiveness of the drug CBD for treating social anxiety disorder?
Who Is on the Research Team?
Naomi Simon, MD
Principal Investigator
NYU Langone Health
Esther Blessing, MD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
Adults aged 18-45 with Social Anxiety Disorder, confirmed by a clinical interview and an LSAS score of at least 60. Participants must not use marijuana or related products during the study and should be free from certain medications for 4 weeks prior. Pregnant women, those with severe medical conditions, metal implants incompatible with MRI, or recent psychotherapy for SAD are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Initial assessments and baseline measurements are conducted
Treatment
Participants receive either CBD 800 mg, CBD 400 mg, or placebo twice daily for three weeks
Week 2 Stress Task
Participants undergo a standardized stress task
Week 3 Imaging Paradigm
Participants undergo a 2-day fear learning and extinction protocol with fMRI
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cannabidiol
- Placebo
Cannabidiol is already approved in United States, European Union, Canada for the following indications:
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Ananda Scientific
Collaborator
National Center for Complementary and Integrative Health (NCCIH)
Collaborator